8-K: Bio-Rad Highlights Droplet Digital PCR Growth Strategy

Bio-Rad Laboratories details its Droplet Digital PCR portfolio, emphasizing its market leadership and future growth opportunities in a recent informational webinar.

Summary

• Bio-Rad hosted an informational webinar on its Droplet Digital PCR (ddPCR) product portfolio on August 26, 2025, featuring President and COO Jon DiVincenzo and CFO Roop K. Lakkaraju.
• ddPCR is presented as the '3rd Gen' evolution of PCR, offering absolute quantification of nucleic acids and enabling rare-event applications like liquid biopsies.
• Bio-Rad commercialized ddPCR in 2010 with the QX100 system and has since achieved the first FDA-Cleared and CE-IVD Registered dPCR system and diagnostic test.
• The company boasts over 12,000 peer-reviewed publications utilizing its ddPCR systems, a figure that has doubled since 2021.
• The absolute quantitation segment size is estimated at approximately $600 million today, with significant growth drivers including early adoption, expanding system use, and proven clinical utility.
• Bio-Rad's ddPCR platforms (QX Continuum, QX700 Series, QX200, QX600, QX ONE, QXDx) cater to diverse needs, from academic research to clinical diagnostics.
• The company maintains an extensive catalog of over 490,000 assays, including 12,500+ validated copy number assays, 34,000+ mutation detection assays, and 445,000+ gene expression assays.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook on Bio-Rad's Droplet Digital PCR technology, emphasizing its market leadership, technological advantages, extensive product portfolio, and significant growth opportunities in critical applications like biopharma and oncology. It highlights the technology's superiority over existing methods and its potential to capture market share.

Positives

• Bio-Rad is a market innovator in digital PCR since 2010, establishing a new standard in absolute quantitation.
• The company offers the first FDA-Cleared and CE-IVD Registered dPCR system and diagnostic test, demonstrating regulatory leadership.
• Droplet Digital PCR technology provides unprecedented levels of precision, accuracy, and resolution, with highly uniform, flexible, and reproducible droplets.
• ddPCR enables life-saving applications in biopharma production (dose control, contaminant testing) and oncology (liquid biopsy, monitoring).
• The absolute quantitation segment is growing, estimated at ~$600 million, driven by increasing adoption and demand for precision.
• Bio-Rad's ddPCR solutions effectively address challenges faced by qPCR (lower sensitivity, variability) and targeted sequencing (high cost, complex workflow).
• An extensive catalog of over 490,000 assays fuels growth and technology conversion, including 60+ validated assays for cell & gene therapy.
• Over 12,000 peer-reviewed publications demonstrate the value and increasing clinical application of Bio-Rad's ddPCR, with a strong shift towards clinical applications.
• The company is well-positioned to capture future growth by accelerating customer shifts from qPCR and NGS to ddPCR.

Risks

• Forward-looking statements are subject to risks and uncertainties, as detailed in the company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Bio-Rad plans to continue growing its existing Droplet Digital PCR business and accelerate the shift of customers from traditional qPCR and Next-Generation Sequencing (NGS) technologies to its ddPCR platforms. The company aims for application expansion, including novel digital PCR tests for cell and gene therapy.

Management Comments

• Our droplet-based approach delivers the highest quality data.
• Droplet Digital PCR provides 'unprecedented levels of precision, accuracy and resolution for quantification of nucleic acids'.
• Droplets are the Benchmark for Precision, Sensitivity, and Reproducibility.
• Droplets Enable Applications that Save Lives.
• Bio-Rad Continues to Lead the Way.
• We will continue to grow our existing business and accelerate customer shift from qPCR and NGS to Droplet Digital PCR.

Industry Context

The filing highlights the evolution of PCR technology from qualitative (1st Gen) to quantitative (qPCR, 2nd Gen) and now to absolute quantification with digital PCR (3rd Gen). It positions ddPCR as a superior solution addressing the limitations of both qPCR (lower sensitivity, variability) and targeted sequencing (high cost, complex workflow) in a growing market for absolute quantitation. The market for absolute quantitation is estimated at $600M, compared to $2.7B for relative quantitation (qPCR) and $2.4B for targeted sequencing (NGS), indicating significant room for ddPCR growth by capturing market share from these other technologies.

Comparison to Industry Standards

• Bio-Rad's ddPCR offers superior sensitivity, reproducibility, and absolute quantification without standards, which are not reliably achievable with traditional qPCR or targeted sequencing (NGS).
• Unlike qPCR, which suffers from lower sensitivity, variability, and relative measurements, ddPCR provides absolute measurements and higher precision.
• Compared to targeted sequencing (NGS), which is characterized by high cost, complex workflows, and long time to result, ddPCR offers cost-effective, simple workflows, fast results, and high sensitivity.
• Bio-Rad's droplet-based approach is highlighted as delivering higher quality data, with droplets being highly uniform, flexible, and reproducible across instruments and labs, setting a benchmark for precision.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share due to the growth of the ddPCR segment and Bio-Rad's strong position within it.
• Customers: Access to advanced, precise, and sensitive molecular diagnostic tools for research, biopharma, and clinical applications.
• Employees: Continued focus on innovation and market leadership in a key product area.

Next Steps

• Continue to grow the existing Droplet Digital PCR business.
• Accelerate customer shift from qPCR and NGS to Droplet Digital PCR.
• Expand applications, including novel digital PCR tests for cell and gene therapy.

Key Dates

Recommendation

This filing is an informational update reinforcing Bio-Rad's strong position in a growing and critical technology segment (ddPCR). While it highlights significant market opportunities and technological advantages, it does not contain new financial results or unexpected strategic shifts that would immediately alter the company's valuation. It serves to confirm the company's strategic direction and product strength, suggesting a 'hold' for investors who already understand the company's fundamentals, as it reinforces the long-term growth thesis without providing new catalysts for an immediate 'buy' or 'sell' decision.

Keywords

Digital PCR, ddPCR, Bio-Rad Laboratories, Molecular Diagnostics, Genomics, Biopharma, Oncology, Liquid Biopsy, Gene Therapy, qPCR, NGS, Absolute Quantification, Life Sciences